HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marina Konopleva Selected Research

Acute Myeloid Leukemia (Acute Myelogenous Leukemia)

4/2022Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy.
4/2022Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
4/2022Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.
1/2022Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
1/2022Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
1/2022Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML.
1/2022AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia.
1/2022Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
1/2022Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy.
1/2022A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marina Konopleva Research Topics

Disease

162Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
04/2022 - 01/2002
100Neoplasms (Cancer)
10/2022 - 07/2002
97Leukemia
04/2022 - 07/2002
53Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
05/2022 - 03/2004
34Philadelphia Chromosome
05/2022 - 10/2006
25Myelodysplastic Syndromes (Myelodysplastic Syndrome)
05/2022 - 09/2006
23Hematologic Neoplasms (Hematological Malignancy)
04/2022 - 01/2002
22BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2022 - 01/2008
15Hypoxia (Hypoxemia)
01/2020 - 08/2009
13B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
12/2021 - 10/2004
13Lymphoma (Lymphomas)
01/2021 - 10/2004
12Acute Promyelocytic Leukemia
01/2022 - 03/2004
10Infections
01/2022 - 03/2004
10Exanthema (Rash)
01/2021 - 07/2015
10Blast Crisis (Blast Phase)
01/2021 - 10/2006
8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
01/2022 - 03/2014
8Residual Neoplasm
01/2021 - 01/2017
7Breast Neoplasms (Breast Cancer)
01/2013 - 03/2003
6Graft vs Host Disease (Graft-Versus-Host Disease)
01/2021 - 05/2007
5Chromosome Aberrations (Chromosome Abnormalities)
01/2022 - 03/2017
5Thrombocytopenia (Thrombopenia)
01/2022 - 01/2018
5Disease Progression
01/2021 - 05/2017
5B-Cell Lymphoma (Lymphoma, B Cell)
01/2021 - 06/2007
5Pathologic Complete Response
07/2020 - 05/2015
4Hypertension (High Blood Pressure)
12/2020 - 01/2011
4Nausea
01/2020 - 07/2015
4Mucositis
01/2019 - 06/2015
4Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
02/2016 - 09/2006
4Neoplasm Metastasis (Metastasis)
03/2014 - 05/2007
4Hyperglycemia
10/2012 - 03/2004
4Pancreatic Neoplasms (Pancreatic Cancer)
09/2010 - 10/2005

Drug/Important Bio-Agent (IBA)

50venetoclaxIBA
05/2022 - 03/2014
47Proteins (Proteins, Gene)FDA Link
10/2021 - 08/2004
26Tyrosine Kinase InhibitorsIBA
04/2022 - 02/2010
23Cytarabine (Cytosar-U)FDA LinkGeneric
05/2022 - 03/2004
18TriterpenesIBA
06/2012 - 01/2002
15Azacitidine (5 Azacytidine)FDA Link
01/2022 - 06/2013
15Phosphotransferases (Kinase)IBA
02/2017 - 04/2006
15bardoxoloneIBA
12/2010 - 01/2002
14Pharmaceutical PreparationsIBA
01/2022 - 08/2004
12bardoxolone methylIBA
08/2014 - 01/2002
11Sorafenib (BAY 43-9006)FDA Link
11/2020 - 02/2008
10AcidsIBA
11/2007 - 09/2003
9ponatinibIBA
05/2022 - 09/2014
8tagraxofuspIBA
10/2022 - 07/2014
8fms-Like Tyrosine Kinase 3IBA
01/2022 - 04/2006
8fludarabineIBA
12/2021 - 08/2006
8Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2021 - 03/2004
8Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric
08/2021 - 11/2013
8Doxorubicin (Adriamycin)FDA LinkGeneric
01/2021 - 03/2003
8DecitabineFDA Link
01/2021 - 09/2012
8Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2019 - 05/2002
7Dasatinib (BMS 354825)FDA Link
05/2022 - 01/2017
7Oxygen (Dioxygen)IBA
10/2021 - 01/2010
7ABT-737IBA
09/2021 - 11/2006
7Biomarkers (Surrogate Marker)IBA
06/2021 - 07/2012
7Vincristine (Oncovin)FDA LinkGeneric
01/2021 - 03/2004
7Fatty Acids (Saturated Fatty Acids)IBA
01/2020 - 01/2010
7Imatinib Mesylate (Gleevec)FDA Link
01/2016 - 10/2006
6blinatumomabIBA
01/2022 - 12/2017
6Inotuzumab OzogamicinIBA
01/2022 - 01/2018
6Clofarabine (Clolar)FDA Link
01/2021 - 09/2012
6LigandsIBA
11/2020 - 07/2002
6ProdrugsIBA
05/2017 - 01/2011
6TOR Serine-Threonine KinasesIBA
11/2015 - 09/2006
6EstersIBA
12/2010 - 01/2002
6PPAR gammaIBA
06/2010 - 07/2002
5Transaminases (Aminotransferases)IBA
10/2022 - 11/2017
5Glutamine (L-Glutamine)FDA Link
01/2022 - 11/2013
5Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2022 - 02/2006
5ibrutinibIBA
12/2021 - 05/2015
5Dexamethasone (Maxidex)FDA LinkGeneric
01/2021 - 03/2004
5Protein Isoforms (Isoforms)IBA
01/2021 - 03/2003
5nutlin 3IBA
01/2017 - 08/2006
5Glucose (Dextrose)FDA LinkGeneric
01/2017 - 03/2004
5bcr-abl Fusion ProteinsIBA
01/2016 - 10/2006
4Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
04/2022 - 12/2011
4Asparaginase (Elspar)FDA Link
01/2022 - 11/2013
4IACS-010759IBA
01/2022 - 01/2018
4GlutaminaseIBA
01/2022 - 11/2016
4CreatinineIBA
01/2022 - 10/2011
4Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
01/2022 - 04/2005
4Granulocyte Colony-Stimulating Factor (G-CSF)IBA
11/2020 - 06/2009
4plerixaforFDA Link
11/2020 - 01/2013
4Adenosine Triphosphate (ATP)IBA
01/2019 - 01/2010
4Tretinoin (Retinoic Acid)FDA LinkGeneric
01/2019 - 12/2007
4Arsenic Trioxide (Trisenox)FDA Link
01/2019 - 05/2015
4CXCR4 Receptors (CXCR4 Receptor)IBA
03/2017 - 03/2007
4Messenger RNA (mRNA)IBA
01/2017 - 06/2010
4Tyrosine (L-Tyrosine)FDA Link
02/2016 - 01/2008
4EverolimusFDA Link
06/2015 - 09/2006
4Sirolimus (Rapamycin)FDA Link
02/2015 - 04/2007
41- (2- cyano- 3,12- dioxooleana- 1,9- dien- 28- oyl) imidazoleIBA
12/2008 - 07/2005
42-cyano-3,12-dioxoolean-1,9-dien-28-oic acidIBA
12/2008 - 04/2004

Therapy/Procedure

106Therapeutics
04/2022 - 09/2003
64Drug Therapy (Chemotherapy)
05/2022 - 11/2004
13Stem Cell Transplantation
10/2021 - 07/2007
6Induction Chemotherapy
09/2019 - 03/2004
5Hematopoietic Stem Cell Transplantation
01/2021 - 05/2007
4Salvage Therapy
01/2021 - 09/2015